Case-Control Study Design in Genetic Epidemiology

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

• Case-control studies in genetic epidemiology compare genetic variant frequencies between affected individuals and carefully selected controls to estimate disease association.
• The critical design decision is control selection, requiring population-representative sampling and explicit matching criteria to minimize selection bias.
• Population stratification remains the most important limitation, and researchers must use ancestry-informative markers or family-based designs to avoid false associations.

At a Glance

Study Design Fundamentals

Defining the Research Question

The case-control design in genetic epidemiology begins with a clearly specified research question that defines the phenotype, the genetic exposure of interest, and the target population. Researchers must articulate whether the study aims to identify novel risk variants, replicate previously reported associations, or estimate the magnitude of a known genetic effect. The specificity of this question determines every subsequent design decision, including case ascertainment, control selection, and statistical analysis.

The phenotype definition requires operational criteria that are reproducible across recruitment sites. For complex diseases, researchers must decide whether to use clinical diagnosis, biomarker-based definitions, or quantitative trait measurements. The choice affects case heterogeneity and statistical power. A narrowly defined phenotype may reduce sample availability but increase the likelihood of detecting genetic effects, while a broad phenotype may increase sample size but dilute true associations.

The Logic of Retrospective Sampling

The case-control design samples individuals based on disease status and retrospectively compares their genetic profiles. This approach is efficient for rare diseases because it enriches the sample for affected individuals. The key assumption is that the genetic variants under study are not influenced by the disease process itself, which holds for germline DNA but requires caution for somatic mutations or epigenetic modifications.

The retrospective sampling scheme introduces the possibility of selection bias because cases and controls are not drawn from the same underlying population. Researchers must document the recruitment pathways for both groups and assess whether participation rates differ by genotype or exposure status. Differential participation can create spurious associations that reflect sampling artifacts instead of true biological effects.

Comparison with Cohort Designs

Cohort designs follow a defined population over time and compare genetic variant frequencies between those who develop disease and those who do not. This prospective approach avoids recall bias and allows for the measurement of environmental exposures before disease onset. However, cohort designs are inefficient for rare diseases because the number of incident cases is small relative to the total cohort size.

The case-control design offers a practical alternative when the disease is rare or when the time to disease onset is long. The tradeoff is that the design relies on retrospective information and may be more susceptible to selection and information bias. Researchers should consider the research question and available resources when choosing between these designs.

Control Selection Strategies

Population-Based Controls

Population-based controls are sampled from the same geographic region and demographic background as the cases. This approach aims to represent the allele frequencies of the underlying population that gave rise to the cases. The sampling frame may be a national registry, electoral roll, or random digit dialing, depending on the study context.

The advantage of population-based controls is that they provide an unbiased estimate of the background allele frequency. The limitation is that they may include individuals who will later develop the disease, which can slightly reduce power but does not introduce bias for rare diseases. Population-based controls also require careful consideration of participation rates, because controls who agree to participate may differ systematically from those who decline.

Hospital-Based Controls

Hospital-based controls are recruited from the same healthcare facilities as the cases, often from patients with other conditions. This approach can improve the comparability of the recruitment process and reduce the cost of control ascertainment. However, the choice of the control condition is critical because the condition may itself have a genetic component that confounds the association.

The selection of hospital controls requires careful exclusion criteria. Controls should not have the disease under study, and the condition that led to their hospitalization should not be associated with the genetic variants of interest. Researchers must document the distribution of control diagnoses and consider whether any of these conditions share genetic architecture with the disease under investigation.

Matching Strategies

Matching is a design strategy that selects controls with the same distribution of certain characteristics as the cases. The purpose of matching is to eliminate confounding by these characteristics and to improve the efficiency of the study. Common matching variables include age, sex, and geographic region.

Frequency matching involves selecting controls so that the distribution of the matching variables is the same as in the cases. Individual matching selects one or more controls for each case with the same values of the matching variables. Individual matching requires a matched analysis, such as conditional logistic regression, to account for the matching structure.

The decision to match on genetic ancestry is important in genetic epidemiology. Matching on ancestry can reduce the risk of population stratification, but it may also reduce the ability to detect associations if the matching variable is correlated with the genetic variant of interest. Researchers should consider the tradeoff between reducing stratification and preserving power.

Population Stratification

Understanding the Confounding Structure

Population stratification occurs when the population under study contains subgroups with different allele frequencies and different disease risks. If cases and controls are not drawn from these subgroups in the same proportions, the allele frequency differences will be attributed to the disease when they actually reflect the population structure.

The confounding arises because ancestry is associated with both the genetic variants and the disease risk. The association between ancestry and disease may be due to environmental factors, social determinants, or other genetic variants. The result is that a genetic variant that is more common in a subgroup with higher disease risk will appear to be associated with the disease, even if the variant has no causal effect.

Detection and Quantification

The first step in addressing population stratification is to detect whether it is present in the study sample. Principal component analysis is a common method for identifying ancestry clusters in the genotype data. The first few principal components often capture the major axes of ancestry variation and can be used as covariates in the analysis.

The detection of stratification requires a set of ancestry-informative markers that are not associated with the disease. These markers should be spread across the genome and have large allele frequency differences between ancestral populations. The number of markers needed depends on the degree of admixture in the population and the desired precision of the ancestry estimates.

Adjustment Methods

Once ancestry is estimated, the analysis can be adjusted for the principal components or other ancestry estimates. The adjustment is performed by including the ancestry variables as covariates in the regression model. This approach assumes that the ancestry variables capture the relevant population structure and that the association between ancestry and disease is linear.

The adjustment for ancestry is not always sufficient. If the population structure is complex or the ancestry estimates are imprecise, residual stratification may remain. In these cases, family-based designs may be more robust because they compare the transmission of alleles from parents to affected offspring, which is not affected by population stratification.

Sample Size and Power

Power Calculation

The power of a case-control study is the probability of detecting a true association, given the sample size, the allele frequency, the effect size, and the significance threshold. The power calculation requires an estimate of the allele frequency in the control population and the expected effect size, which is often expressed as an odds ratio.

The effect size for a genetic variant is typically small, with odds ratios in the range of 1.1 to 1.5 for common variants. The required sample size increases as the effect size decreases and as the allele frequency becomes more extreme. The power calculation should also account for the number of variants tested, because multiple testing increases the significance threshold and reduces power.

Sample Size Considerations

The sample size for a case-control study is determined by the power calculation and the available resources. The sample size must be large enough to detect the expected effect size with adequate power, typically 80 percent or higher. The sample size also depends on the ratio of cases to controls, with an optimal ratio of approximately 1:1 for most designs.

The sample size calculation should be performed before the study begins and should be documented in the study protocol. The calculation should include the assumptions about allele frequency and effect size, and the sensitivity of the power to these assumptions should be explored. If the expected effect size is uncertain, the sample size may need to be increased to account for the uncertainty.

Replication and Meta-Analysis

The replication of findings in independent samples is a key step in genetic epidemiology. A single study may produce a false-positive result due to chance or bias, and replication provides evidence that the association is real. The replication study should use the same phenotype definition and the same genetic variant, and the analysis should be consistent with the original study.

Meta-analysis combines the results of multiple studies to increase the sample size and the power to detect associations. The meta-analysis requires that the studies are comparable in terms of the phenotype, the genetic variant, and the analysis. The heterogeneity between studies should be assessed, and the results should be interpreted in the context of the heterogeneity.

Genotyping and Quality Control

Genotyping Platforms

The choice of genotyping platform determines the number of variants that can be assessed and the cost of the study. The platform may be a fixed array that measures a set of known variants or a sequencing approach that can identify novel variants. The choice of platform should be based on the research question and the available resources.

The genotyping platform must be consistent across all samples in the study. If different platforms are used for cases and controls, the differences in the platforms can introduce bias. The genotyping should be performed in a single batch or in a randomized order to minimize the effects of batch variation.

Quality Control Metrics

The quality control of the genotype data is essential to ensure the accuracy of the results. The quality control includes the assessment of the call rate, the Hardy-Weinberg equilibrium, and the heterozygosity of the samples. The call rate is the proportion of variants that are successfully genotyped for each sample, and samples with low call rates should be excluded.

The Hardy-Weinberg equilibrium is a measure of the genotype frequencies in the population. Deviations from the equilibrium can indicate genotyping errors or population structure. The heterozygosity of the sample is a measure of the proportion of heterozygous genotypes, and samples with extreme heterozygosity may be contaminated or have other issues.

Batch Effects

Batch effects are systematic differences in the genotype data that are due to the processing of the samples in different batches. The batch effects can be caused by differences in the reagents, the equipment, or the laboratory conditions. The batch effects can introduce bias if the cases and controls are processed in different batches.

The batch effects can be minimized by randomizing the samples across the batches and by including control samples in each batch. The batch effects can be detected by comparing the genotype distributions across the batches and can be adjusted for in the analysis using statistical methods.

Analysis Methods

Single-Variant Analysis

The single-variant analysis tests the association between each variant and the disease status. The analysis is typically performed using a logistic regression model that includes the genotype as the predictor and the disease as the outcome. The model can include covariates such as age, sex, and ancestry to adjust for confounding.

The single-variant analysis is simple and computationally efficient, but it may not be powerful for rare variants. The analysis of rare variants requires the aggregation of multiple variants in a gene or a region, because the individual variants have too few observations to be tested individually.

Gene-Based and Pathway-Based Analysis

The gene-based analysis combines the variants in a gene to test the association between the gene and the disease. The analysis can be performed using a burden test, which counts the number of rare variants in the gene, or a variance-component test, which tests the distribution of the variants. The gene-based analysis increases the power to detect associations with rare variants.

The pathway-based analysis combines the variants in a biological pathway to test the association between the pathway and the disease. The analysis can be performed using a gene-set enrichment approach, which tests whether the genes in the pathway are overrepresented among the associated variants. The pathway-based analysis can provide insight into the biological mechanisms of the disease.

Adjustment for Multiple Testing

The testing of many variants in a single study requires the adjustment for multiple testing to control the false-positive rate. The adjustment can be performed using the Bonferroni correction, which divides the significance threshold by the number of tests, or the false discovery rate, which controls the proportion of false positives among the significant results.

The choice of the adjustment method depends on the research question and the number of tests. The Bonferroni correction is conservative and may reduce the power to detect true associations. The false discovery rate is less conservative and may be more appropriate for exploratory analyses.

Reporting and Reproducibility

Reporting Guidelines

The reporting of the case-control study should follow the guidelines for the reporting of observational studies. The guidelines provide a checklist of items that should be included in the report, including the study design, the sample size, the genotyping methods, and the analysis. The guidelines are intended to improve the transparency and the reproducibility of the research.

The reporting guidelines are available from the EQUATOR Network, which is a repository of reporting guidelines for health research. The guidelines should be consulted before the study begins and should be used to guide the writing of the report. The adherence to the guidelines is a marker of the quality of the research.

Data Sharing and Management

The sharing of the data is a requirement for many funding agencies and journals. The data sharing allows other researchers to replicate the analysis and to combine the data with other studies. The data sharing should be performed in a way that protects the privacy of the participants and the confidentiality of the data.

The data management plan should be developed before the study begins and should describe the data collection, the storage, and the sharing. The plan should be consistent with the policies of the funding agency and the institution. The plan should also address the long-term preservation of the data and the access to the data.

Researcher Identity and Attribution

The researcher identity is important for the attribution of the work and the tracking of the research output. The ORCID identifier provides a unique identifier for each researcher and can be used to link the researcher to their publications and other research activities. The ORCID identifier should be included in the manuscript and in the data sharing.

The researcher identity is also important for the peer review process. The reviewers should be able to verify the identity of the authors and to assess the potential conflicts of interest. The conflicts of interest should be disclosed in the manuscript and should be managed according to the policies of the journal.

Common Failure Patterns

Inadequate Control Selection

The most common failure in the case-control design is the selection of controls that are not representative of the population that gave rise to the cases. The controls may be selected from a different geographic region, a different age group, or a different socioeconomic status. The bias can be introduced if the control selection is not carefully planned.

The failure can be detected by comparing the allele frequencies of the controls with the expected frequencies in the population. The failure can be prevented by using a population-based sampling frame and by documenting the recruitment pathways. The failure can be corrected by the analysis if the bias is identified.

Population Stratification

The population stratification is a common failure in the case-control design, particularly in populations with a high degree of admixture. The stratification can be introduced if the cases and controls are not matched on ancestry or if the ancestry is not adjusted for in the analysis. The stratification can produce false-positive associations that are not reproducible.

The failure can be detected by the principal component analysis and by the genomic inflation factor. The failure can be prevented by the matching on ancestry or by the adjustment for ancestry in the analysis. The failure can be addressed by the family-based design, which is not affected by the stratification.

Genotyping Errors

The genotyping errors can be introduced during the genotyping process or during the data processing. The errors can be caused by the contamination of the samples, the failure of the genotyping assay, or the errors in the data entry. The errors can produce false-positive or false-negative associations.

The failure can be detected by the quality control metrics, such as the call rate and the Hardy-Weinberg equilibrium. The failure can be prevented by the use of standardized protocols and by the randomization of the samples. The failure can be addressed by the exclusion of the samples with low quality.

Overmatching

The overmatching occurs when the matching variable is associated with the exposure but not with the disease. The overmatching can reduce the power of the study and can obscure the true association. The overmatching can occur when the matching variable is a genetic variant that is associated with the disease.

The failure can be detected by the examination of the association between the matching variable and the disease. The failure can be prevented by the careful selection of the matching variables and by the consideration of the biological plausibility. The failure can be addressed by the analysis of the data without the matching variable.

Limitations and Interpretation

The Limits of the Case-Control Design

The case-control design is subject to several limitations that should be considered when interpreting the results. The design is susceptible to selection bias, information bias, and confounding. The design cannot establish the temporal relationship between the exposure and the disease, and the design is not suitable for the study of rare exposures.

The limitations should be acknowledged in the report and should be considered when the results are interpreted. The limitations should not be used to dismiss the results, but they should be used to the interpretation of the results. The limitations should be addressed in the discussion and the recommendations for the future research.

The Interpretation of the Association

The association between a genetic variant and a disease does not necessarily imply a causal relationship. The association may be due to the linkage disequilibrium with a causal variant, the population stratification, or the confounding. The interpretation of the association should consider the biological plausibility and the evidence from the functional studies.

The interpretation of the association should also consider the effect size and the confidence interval. The effect size is the magnitude of the association, and the confidence interval is the range of the plausible values. The interpretation should be cautious when the effect size is small or the confidence interval is wide.

The Generalizability of the Results

The results of a case-control study are specific to the population that was studied. The results may not be generalizable to other populations with different allele frequencies or different environmental exposures. The generalizability of the results should be considered when the results are applied to other populations.

The generalizability of the results can be improved by the replication of the study in other populations. The replication can provide evidence that the association is consistent across the populations. The replication can also identify the differences in the association that are due to the population-specific factors.

A Practical Decision Framework for Case-Control Study Design

The Design Decision Matrix

The transition from study concept to a working case-control design requires a structured decision process that forces explicit choices at each step. A decision matrix helps the research team document the rationale for each design choice and creates an audit trail that supports later reporting and replication. The matrix should be completed before recruitment begins and updated whenever a design element changes.

The matrix organizes the design process into five sequential decision points. The first decision point is the phenotype definition, which requires a written operational criteria document that specifies the diagnostic method, the severity threshold, and the exclusion criteria. The second decision point is the case ascertainment pathway, which requires a documented recruitment protocol that identifies the source population and the referral pattern. The third decision point is the control selection strategy, which requires a written sampling plan that specifies the sampling frame, the matching variables, and the exclusion criteria. The fourth decision point is the genotyping plan, which requires a specification of the platform, the quality thresholds, and the batch randomization scheme. The fifth decision point is the analysis plan, which requires a pre-specified statistical model that includes the covariates, the multiple testing correction, and the sensitivity analyses.

Each decision point in the matrix should include a primary choice, an alternative choice, and a trigger for reconsideration. The trigger condition is the observation or event that would cause the team to revisit the decision. For example, the control selection strategy may need to be revised if the participation rate falls below a threshold that was specified in the protocol. The decision matrix should be reviewed at regular intervals during the study and the review should be documented in the study log.

The Control Selection Decision Tree

The control selection decision tree provides a stepwise approach to choosing between population-based and hospital-based controls. The first branch of the tree asks whether a population-based sampling frame is available and affordable. If the answer is yes, the population-based approach is preferred because it provides the most unbiased estimate of the background allele frequency. If the answer is no, the hospital-based approach is considered.

The second branch of the tree asks whether the hospital-based controls can be selected from conditions that are unrelated to the genetic variants of interest. The research team must list the candidate control conditions and assess each one for a potential genetic relationship with the disease under study. The assessment should be based on the published literature and the biological plausibility. If any of the candidate conditions share genetic architecture with the disease, the condition should be excluded from the control pool.

The third branch of the tree asks whether the hospital-based controls can be matched to the cases on the key demographic variables. The matching variables should be limited to those that are known confounders, such as age, sex, and geographic region. The matching on variables that are not confounders should be avoided because it reduces the power without improving the validity.

The fourth branch of the tree asks whether the control recruitment pathway can be documented and monitored. The research team must record the number of eligible controls, the number who were approached, and the number who agreed to participate. The participation rate should be compared between the cases and the controls, and the differences should be assessed for the potential to introduce bias.

The Population Stratification Assessment Protocol

The population stratification assessment protocol is a standardized procedure for detecting and quantifying the ancestry structure in the study sample. The protocol should be implemented before the primary analysis and the results should be documented in the study log. The protocol has four steps.

The first step is the selection of the ancestry-informative markers. The markers should be spread across the genome and should have large allele frequency differences between the ancestral populations. The number of markers should be sufficient to estimate the ancestry with the desired precision, and the markers should not be associated with the disease under study.

The second step is the estimation of the ancestry for each sample. The estimation can be performed using a principal component analysis or a model-based clustering method. The principal component analysis is computationally efficient and is appropriate for most studies. The model-based clustering method can provide a more detailed ancestry estimate but requires more computational resources.

The third step is the assessment of the ancestry distribution in the cases and the controls. The distribution should be compared using a statistical test, such as the chi-square test or the analysis of variance. The comparison should be performed for each principal component and the results should be reported.

The fourth step is the decision about the analysis strategy. If the ancestry distribution differs between the cases and the controls, the analysis should be adjusted for the ancestry. The adjustment can be performed by including the principal components as covariates in the regression model. If the ancestry distribution is similar, the adjustment may not be necessary, but the sensitivity of the results to the adjustment should be explored.

The Genotyping Quality Control Workflow

The genotyping quality control workflow is a sequence of checks that are applied to the genotype data before the analysis. The workflow should be specified in the study protocol and the results of each check should be recorded in the quality control log. The workflow has five steps.

The first step is the sample-level quality control. The call rate is calculated for each sample and the samples with a call rate below the threshold are excluded. The threshold should be specified in the protocol and should be based on the genotyping platform and the expected performance. The heterozygosity of each sample is also calculated and the samples with extreme heterozygosity are flagged for review.

The second step is the variant-level quality control. The call rate is calculated for each variant and the variants with a call rate below the threshold are excluded. The Hardy-Weinberg equilibrium is tested in the controls and the variants with a significant deviation are flagged for review. The minor allele frequency is calculated and the variants with a very low frequency are excluded from the analysis.

The third step is the batch effect assessment. The genotype distributions are compared across the batches and the differences are tested for significance. The batch effects can be detected by the principal component analysis of the genotype data, and the batch variables can be included as covariates in the analysis.

The fourth step is the sample relatedness check. The relatedness between the samples is estimated using the identity-by-descent analysis. The samples that are closely related are identified and one of the related samples is excluded from the analysis. The relatedness check is important because the inclusion of related samples can inflate the test statistics and produce false-positive associations.

The fifth step is the sex check. The sex of each sample is estimated from the genotype data and compared with the recorded sex. The samples with a discrepancy are flagged for review and the discrepancy is resolved by the re-examination of the sample records.

The Study Log and Documentation System

The study log is the central record of the design decisions, the recruitment progress, and the quality control results. The log should be maintained throughout the study and should be available for the review by the research team and the auditors. The log should be organized into sections that correspond to the decision matrix and the quality control workflow.

The first section of the log is the design decisions section. This section records the phenotype definition, the case ascertainment method, the control selection strategy, the genotyping strategy, and the analysis plan. Each decision should be dated and the rationale should be recorded.

The second section of the log is the recruitment section. This section records the number of cases and controls who were approached, the number who agreed to participate, and the number who completed the study. The recruitment rates should be calculated and the differences between the cases and the controls should be recorded.

The third section of the log is the quality control section. This section records the results of the sample-level, variant-level, batch, relatedness, and sex checks. The samples and the variants that are excluded should be recorded with the reason for the exclusion.

The fourth section of the log is the analysis section. This section records the analysis plan, the results of the primary analysis, and the results of the sensitivity analyses. The section should also record the version of the analysis software and the parameters that are used.

The study log should be maintained in a secure location and the access should be restricted to the research team. The log should be backed up regularly and the backup should be stored in a separate location. The log should be retained for the duration of the study and for the period that is required by the funding agency and the institution.

The Troubleshooting Protocol

The troubleshooting protocol is a structured approach to identifying and resolving the problems that arise during the study. The protocol should be implemented when the monitoring indicates a problem and the resolution should be documented in the study log. The protocol has four steps.

The first step is the problem identification. The problem is identified by the monitoring of the recruitment, the quality control, or the analysis. The problem should be described in the study log with the date and the relevant data.

The second step is the problem assessment. The research team should assess the impact of the problem on the validity of the study. The assessment should consider the potential for bias and the potential for the loss of power. The assessment should be documented in the study log.

The third step is the problem resolution. The research team should identify the possible solutions and select the solution that is most appropriate. The solution should be implemented and the implementation should be documented in the study log.

The fourth step is the problem prevention. The research team should identify the changes that are needed to prevent the problem from recurring. The changes should be implemented and the implementation should be documented in the study log.

The monitoring protocol should be reviewed at the regular intervals and the review should be documented in the study log. The review should include the assessment of the recruitment progress, the quality control results, and the analysis results. The review should also include the assessment of the compliance with the study protocol and the reporting guidelines.

The Escalation Criteria

The escalation criteria define the conditions under which the research team should seek the advice of the external experts or the institutional review board. The escalation criteria should be specified in the study protocol and the escalation should be documented in the study log. The escalation criteria include the following conditions.

The first escalation condition is the evidence of the differential participation between the cases and the controls. If the participation rate differs by more than the threshold that is specified in the protocol, the research team should escalate the issue to the external experts. The differential participation can introduce the selection bias and the bias should be assessed.

The second escalation condition is the evidence of the population stratification that cannot be resolved by the adjustment. If the ancestry distribution differs between the cases and the controls and the adjustment does not remove the difference, the research team should escalate the issue. The residual stratification may require the family-based design or the additional ancestry markers.

The third escalation condition is the evidence of the genotyping error that cannot be resolved by the quality control. If the quality control identifies the errors that cannot be resolved by the re-genotyping or the exclusion, the research team should escalate the issue. The genotyping error may require the re-genotyping of the samples or the use of the different platform.

The fourth escalation condition is the evidence of the relatedness that cannot be resolved by the exclusion. If the relatedness check identifies the related samples that cannot be excluded without the loss of the power, the research team should escalate the issue. The relatedness may require the use of the analysis method that accounts for the relatedness.

The escalation should be documented in the study log and the advice of the external experts should be recorded. The advice should be implemented and the implementation should be documented. The escalation should be reported to the institutional review board if the issue affects the safety or the welfare of the participants.

The Reporting and Publication Checklist

The reporting and publication checklist is a practical tool for ensuring that the study report includes all the information that is needed for the interpretation and the replication. The checklist should be used during the writing of the report and the completed checklist should be submitted with the manuscript. The checklist is based on the reporting guidelines that are available from the EQUATOR Network.

The checklist includes the following items. The first item is the study design, which should describe the case-control design and the rationale for the design. The second item is the study population, which should describe the source population, the recruitment pathway, and the inclusion and exclusion criteria. The third item is the control selection, which should describe the sampling frame, the matching variables, and the exclusion criteria. The fourth item is the genotyping, which should describe the platform, the quality control, and the batch randomization. The fifth item is the analysis, which should describe the primary analysis, the ancestry adjustment, and the sensitivity analyses.

The checklist should be completed by the research team and the completed checklist should be reviewed by the co-authors. The checklist should be submitted with the manuscript and the journal should be informed of the checklist. The checklist should be updated if the manuscript is revised.

The reporting checklist should be used in conjunction with the data management plan. The data management plan should describe the data collection, the storage, and the sharing. The plan should be consistent with the policies of the funding agency and the institution. The plan should also address the long-term preservation of the data and the access to the data.

The data management plan should be developed before the study begins and should be updated as the study progresses. The plan should be submitted to the funding agency and the institution. The plan should be reviewed by the research team and the review should be documented in the study log.

The data sharing should be performed in a way that protects the privacy of the participants and the confidentiality of the data. The data should be de-identified before the sharing and the de-identification should be documented. The data should be shared in a repository that is approved by the funding agency and the institution. The data should be shared with the research community and the sharing should be documented in the study log.

The researcher identity should be established using the ORCID identifier. The ORCID identifier should be included in the manuscript and in the data sharing. The ORCID identifier should be used to link the researcher to the publications and the research activities. The ORCID identifier should be maintained and the record should be updated.

The publication ethics should be followed throughout the study. The authorship should be determined according to the criteria that are specified by the Committee on Publication Ethics. The authorship should be agreed upon before the manuscript is submitted. The conflicts of interest should be disclosed and the disclosure should be documented. The data should be reported accurately and the misconduct should be reported to the appropriate authority.

Frequently Asked Questions

What is the difference between a case-control study and a cohort study in genetic epidemiology?

A case-control study samples individuals based on disease status and compares their genetic variant distributions, while a cohort study follows a population over time and compares those who develop disease with those who do not. The case-control design is more efficient for rare diseases, while the cohort design avoids selection bias and allows for temporal exposure measurement.

How do I select controls for a genetic case-control study?

Controls should be drawn from the same source population as the cases, using a population-based sampling frame or a hospital-based approach with careful exclusion criteria. The controls should be matched on key characteristics such as age, sex, and ancestry, and the matching strategy should be documented in the study protocol.

What is population stratification and why does it matter?

Population stratification is the confounding of the association between a genetic variant and disease by ancestry. It occurs when the population contains subgroups with different allele frequencies and different disease risks, and it can produce false-positive associations. The stratification can be addressed by the adjustment for ancestry or by the family-based design.

How do I calculate the sample size for a case-control study?

The sample size is calculated based on the expected allele frequency, the effect size, the significance threshold, and the desired power. The calculation should be performed before the study begins and should be documented in the protocol. The sample size should be adjusted for the number of variants tested and the expected heterogeneity.

What quality control measures should I use for genotyping data?

The quality control measures include the call rate, the Hardy-Weinberg equilibrium, and the heterozygosity of the samples. The samples with low call rates or extreme heterozygosity should be excluded. The batch effects should be minimized by the randomization of the samples and the inclusion of the control samples.

How do I address population stratification in the analysis?

The population stratification can be addressed by the estimation of the ancestry using the principal component analysis and the inclusion of the ancestry as covariates in the analysis. The family-based design can also be used to avoid the stratification. The residual stratification should be assessed using the genomic inflation factor.

What are the reporting guidelines for a case-control study?

The reporting guidelines provide a checklist of items that should be included in the report, such as the study design, the sample size, the genotyping, and the analysis. The guidelines are available from the EQUATOR Network and should be consulted during the study and used during the writing of the report.

How do I ensure the reproducibility of my case-control study?

The reproducibility can be ensured by the documentation of the study design, the data collection, and the analysis. The data should be shared in a way that protects the privacy of the participants, and the analysis should be transparent. The researcher identity should be established using the ORCID identifier.

Using the Evidence

Related Diagnostic Guides

• Case-Control Studies in Veterinary Epidemiology: Selection and Analysis
• Clinical Chemistry Interference Studies: Design and Interpretation
• Clinical Chemistry Case Studies: Interpreting Results and Diagnosing Disorders
• Clinical Chemistry Case Studies: Applying Laboratory Data to Patient Care

References and Further Reading

• Research Methods Resources. National Library of Medicine.
• EQUATOR Network. EQUATOR Network.
• Core Practices. Committee on Publication Ethics.
• NIH Grants and Funding. National Institutes of Health.
• ORCID for Researchers. ORCID.
• Data Management and Sharing Policy. National Institutes of Health.
• Laboratory Biosafety Manual. World Health Organization.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Genetic epidemiology of COPD (COPDGene) study design.. COPD, 2010.
• Data quality control in genetic case-control association studies.. Nature protocols, 2010.
• Inflammatory Biomarkers and Risk of Psychiatric Disorders.. JAMA psychiatry, 2024.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.